Author: Victoria Stern

Why did it take a journal two years to retract a paper after a misconduct finding?

A 2014 paper containing data manipulated by a former graduate student has finally been retracted, two years after the U.S. Office of Research Integrity (ORI) published its findings.

In August 2015, the ORI published a report that Peter Littlefield, who was working on his PhD at the University of California, San Francisco (UCSF), had committed “research misconduct by falsifying and/or fabricating data” in two papers. Littlefield agreed to correct or retract the papers–one published in Chemistry & Biology and the other in Science Signaling.  

When we contacted Chemistry & Biology back in August 2015, a spokesperson for Cell Press told us the journal was figuring out “the best way to correct the scientific record.”

Apparently that took two years. In the meantime, the journal did not issue an expression of concern or otherwise notify readers of the issues. Continue reading Why did it take a journal two years to retract a paper after a misconduct finding?

PLOS ONE retracts paper after researcher admits to fabricating data

On June 19, 2017, the U.S. Office of Research Integrity published its first misconduct finding of the year. The ORI reported that Brandi M. Baughman — a former research training awardee at the National Institute of Environmental and Health Sciences (NIEHS) — had “falsified and/or fabricated data” in 11 figures in a 2016 paper published in PLOS ONE.

Two days later, on June 21, PLOS ONE retracted the paper. (Note: The retraction process proceeded relatively quickly, but took longer than two days; a spokesperson for the journal told us that the authors alerted the editors of their concerns about the publication in May.)   Continue reading PLOS ONE retracts paper after researcher admits to fabricating data

Uni dings schizophrenia studies for problems with informed consent, other flaws

Psychiatry journals have retracted two papers evaluating a schizophrenia drug after a university in Japan flagged issues, such as a lack of written informed consent.

The papers—published in Human Psychopharmacology: Clinical & Experimental in 2012 and Psychiatry and Clinical Neurosciences in 2014—examined the safety and effectiveness of an antipsychotic drug in patients with schizophrenia.

According to the retraction notice in Psychiatry and Clinical Neurosciences, the ethics committee at St. Marianna University School of Medicine in Kawasaki found that “the trial included subjects who did not satisfy inclusion criteria.” For instance, not all patients provided written informed consent. But the university found no evidence for data falsification or fabrication.

A spokesperson for Human Psychopharmacology told us: Continue reading Uni dings schizophrenia studies for problems with informed consent, other flaws

NIH section chief with 19 retractions is no longer running a lab

Stanley Rapoport.
Source: NIH

A former section chief at the National Institutes of Health who has had 19 papers retracted is no longer running a lab, Retraction Watch has learned.

In the last three years, Stanley Rapoport, who is based at the U.S. National Institute on Aging (NIA), has lost 19 papers due to the misconduct of three different co-authors—Jagadeesh Rao, Fei Gao and Mireille Basselin.

And now, Rapoport, who was chief of the brain physiology and metabolism section of the NIA, no longer runs a lab.

According to a spokesperson at the NIA: Continue reading NIH section chief with 19 retractions is no longer running a lab

Work by group at Australian university faces scrutiny

A journal is investigating research by a group in Australia, after receiving “serious allegations” regarding a 2017 paper about treating eye burns.

The journal, Frontiers in Pharmacology, has issued an expression of concern (EOC) for the 2017 paper while it investigates. The notice does not specify the nature of the allegations.  Meanwhile, several other papers by the three researchers, based at Deakin University in Geelong, Australia, have also come under scrutiny. Late last month, Frontiers in Pharmacology retracted a 2015 paper by Kislay Roy, Rupinder Kanwar, and Jagat R Kanwar, citing image duplication. A 2015 paper in Biomaterials received a correction in May 2017, again flagging image duplication.

Roy, the first author on the papers, is a postdoctoral research fellow; Rupinder Kanwar, a middle author, is a senior lecturer; and Jagat R Kanwar, the corresponding author on all three, is head of the Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research.

Gearóid Ó Faoleán, the ethics and integrity manager at Frontiers in Pharmacology, explained that the investigation into the flagged article is ongoing and the EOC “must serve as the extent of our public statement for the present.”

A spokesperson for Deakin University declined to comment on the allegations: Continue reading Work by group at Australian university faces scrutiny

Months after neuroscientist flagged errors, Nature journal corrects them — and more

When a neuroscientist noticed there were problems with his January 2017 paper in Nature Neuroscience, he didn’t wait for the journal to take action — instead, he published his concerns about four figures on PubMed Commons. Months later, the journal has issued formal corrections to those figures — along with several more.   

In February 2017, we praised Garret Stuber for alerting the scientific community to issues in his paper only 10 days after it first appeared online. On Twitter, he directed followers to the comment on PubMed Commons and asked them to retweet “for the sake of science integrity” — yet another example of how more researchers are taking matters into their own hands to alert readers to flaws in their papers. But according to the journal, the problems with the paper were more extensive than Stuber initially reported. Continue reading Months after neuroscientist flagged errors, Nature journal corrects them — and more

Jumped the gun: Paper about non-finalized guidelines is retracted

Too soon? A surgeon is retracting his overview of new hernia surgery guidelines after it was published before the guidelines were finalized.

The paper, published in German in the journal, Der Chirurg, was also retracted because — according to two co-authors of the new guidelines — the final version of the guidelines was supposed to appear first, in English, in another journal.

The author of the paper, Dirk Weyhe, explained that the journal invited him to write an overview of the new guidelines for a special issue. According to Weyhe, a surgeon based in Germany who was a co-author on the guidelines, the aim of the special issue was to follow-up on an agreement reached at an international hernia conference in 2016: Continue reading Jumped the gun: Paper about non-finalized guidelines is retracted

“We do not want to create false hope”: Authors retract Cell paper they can’t replicate

A few years ago, researchers in Sweden had something to celebrate: They thought they had discovered a chink in the armor of the most common type of malignant brain cancer.

In a 2014 Cell paper, the team — led by Patrik Ernfors at the Karolinska Institutet — reported that they had identified a small molecule that could target and kill glioblastoma cells — the cancer that U.S. Senator John McCain was just diagnosed with — and prolong survival in mice with the disease. 

Satish Srinivas Kitambi, the paper’s first author, who is also based at the Karolinska Institutet, said the results got the team “really excited:” Continue reading “We do not want to create false hope”: Authors retract Cell paper they can’t replicate

Science journal flags cancer paper under investigation for image manipulation

Science Signaling has issued an expression of concern for a 2016 paper, citing an institutional investigation into image manipulation.

According to a spokesperson for the journal, the corresponding author, Tanya Kalin, became concerned that two images in the paper had been manipulated. Kalin then notified the research integrity officer at Cincinnati Children’s Hospital Medical Center, where she is based.

On May 9 2017, Kalin alerted the journal to the investigation. A week later, the hospital’s research integrity officer followed up with the journal, flagging the figures under question.  The journal then prepared an expression of concern (EOC) to alert readers to the issues and the institution’s investigation.  

Here’s the EOC notice for “The transcription factor FOXF1 promotes prostate cancer by stimulating the mitogen-activated protein kinase ERK5:” Continue reading Science journal flags cancer paper under investigation for image manipulation

NIH neuroscientist up to 19 retractions

Stanley Rapoport.
Source: NIH

The string of apparent bad luck continues for Stanley Rapoport.

Rapoport, a neuroscientist based at the U.S. National Institute on Aging, has lost three more papers in three journals due to the misconduct of his co-authors. By our count, these retractions bring his tally to 19 — and tie him for 21st place on our leaderboard.

The journals—Schizophrenia Research, Journal of Affective Disorders, and Biological Psychiatry— retracted the papers because the National Institutes of Health had found that one of Rapoport’s co-authors, Jagadeesh Rao, had “engaged in research misconduct by falsifying data.” Rao was corresponding author on all three papers.

According to a spokesperson for Elsevier, which publishes the journals, the Schizophrenia Research paper was retracted in July, the JAD paper in late May and the Biological Psychiatry paper in late April. The spokesperson told us that the publisher first received an email from the NIH about the misconduct findings on September 20, 2016, and that: Continue reading NIH neuroscientist up to 19 retractions